Last reviewed · How we verify
NCT06706700: EMI-IPMN
Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia/invasive Carcinoma in Patients with IPMN of the Pancreas
trial in Intraductal Papillary Mucinous Neoplasm of Pancreas in 586 participants. Currently enrolling.
31 January 2025
Quick facts
| Lead sponsor | IRCCS San Raffaele |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 586 |
| Start date | 13 July 2020 |
| Primary completion | 31 January 2025 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across Italy |
Conditions studied
- Intraductal Papillary Mucinous Neoplasm of Pancreas — all drugs for Intraductal Papillary Mucinous Neoplasm of Pancreas →
- Pancreatic Cyst — all drugs for Pancreatic Cyst →
Sponsor
IRCCS San Raffaele — full company profile →
Who can join
18 and older, any sex, with Intraductal Papillary Mucinous Neoplasm of Pancreas or Pancreatic Cyst. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Under the hypotheses that a more accurate patients selection could limit the problem of overtreatment and that benign intraductal papillary mucinous neoplasms (IPMN) have a distinguishable Endocrine/Metabolic/Inflammatory (EMI) profile from those with high-grade disease/invasive carcinoma, this study has three specific aims. The first aim is to evaluate and confirm the accuracy of the updated versions of International and European guidelines for the management of IPMN and it will be addressed by retrospectively applying the criteria included in the two guidelines on 350 patients with resected IPMN in order to determine the most accurate criteria to identify High Grade Dysplasia(HGD)/Invasive Carcinoma (IC). The second aim is to identify pre-operative biological and/or radiological/endosonographic biomarker(s) able to distinguish low- versus high-risk IPMN for cancer progression in a prospective study by enrolling a cohort of 186 (of which 145 surgically-resected) patients. The third aim is to prospectively validate biological and/or radiological/endosonographic biomarker(s) (previously identified and optimized) on a new cohort of 50 patients with IPMN undergoing surgical resection.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset.
Allgöwer C, Mulaw MA, Nagai J, Wiedenmann S, et al · · 2026 · cited 1× · PMID 41634803 · DOI 10.1186/s12943-025-02541-1 -
UEG Week 2025 Oral Presentations
· 2025
Verify or expand the search:
- PubMed search for NCT06706700
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other IRCCS San Raffaele trials
Trials by the same sponsor.
- NCT07454759 — Acute Sarcopenia in Hospitalized Older Adults · not yet recruiting
- NCT07456462 — Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance · NA · not yet recruiting
- NCT07066878 — This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life B · not yet recruiting
- NCT07526298 — Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Ap · not yet recruiting
- NCT07426471 — Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06706700 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS San Raffaele
- Last refreshed: 26 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06706700.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing